Primary progressive multiple sclerosis (PPMS) is a form of multiple sclerosis where symptoms gradually worsen over time from the very beginning, without the typical pattern of relapses and remissions seen in other types of MS. Treatment focuses on slowing disability progression, managing symptoms, and maintaining quality of life through both approved therapies and promising approaches currently being studied in clinical trials.

Understanding How PPMS Is Treated Today

When someone receives a diagnosis of primary progressive multiple sclerosis, the focus of treatment shifts to a very specific set of goals. Unlike other forms of MS where doctors aim to prevent relapses, treatment for PPMS centers on slowing down the steady progression of disability that characterizes this condition. The aim is to help people maintain their mobility, independence, and overall quality of life for as long as possible.^[1]

Treatment approaches vary significantly from person to person because PPMS affects everyone differently. Some people experience a relatively slow progression of symptoms, while others face more rapid changes. Doctors consider many factors when creating a treatment plan, including how long someone has had symptoms, what specific difficulties they’re facing, and their overall health status. The unpredictable nature of this condition means that regular monitoring and adjustment of treatment strategies are essential parts of care.^[10]

Medical societies and neurological organizations have developed guidelines for treating PPMS based on years of research and clinical experience. These recommendations recognize that while there are limited options specifically approved for PPMS, there are many ways to address the symptoms that develop. The treatment landscape includes both disease-modifying therapies that target the underlying disease process and symptomatic treatments that help manage day-to-day challenges. Additionally, researchers around the world are actively testing new therapeutic approaches in clinical trials, offering hope for expanded treatment options in the future.^[7]

The treatment journey for PPMS typically involves a team of healthcare providers, including neurologists, physical therapists, occupational therapists, and other specialists. This comprehensive approach addresses not just the disease itself, but also the physical, emotional, and practical challenges that come with living with a progressive neurological condition. Regular assessments help track disease progression and guide decisions about when to adjust treatment or add supportive therapies.^[11]

Standard Treatment Options

The treatment landscape for primary progressive multiple sclerosis is notably different from that of relapsing-remitting MS. For many years, there were no approved medications specifically designed to slow the progression of PPMS. This changed when ocrelizumab became the first and currently only drug approved by regulatory authorities for treating this form of the disease. This medication represents a significant milestone in PPMS care, offering the first targeted approach to slow disease progression.^[7]

Ocrelizumab is a type of medication known as a monoclonal antibody, which means it’s a laboratory-made protein that targets specific cells in the immune system. In the case of ocrelizumab, it works by destroying certain B cells, which are white blood cells that play a role in the immune system’s mistaken attack on the nervous system in MS. By reducing these specific immune cells, the medication aims to slow down the nerve damage that causes disability progression in PPMS.^[11]

The medication is given through an intravenous infusion, meaning it’s delivered directly into a vein over several hours. The treatment schedule involves two initial doses given two weeks apart, followed by single infusions every six months thereafter. During and after each infusion, patients are monitored carefully for any reactions. Recently, a subcutaneous version called Ocrevus Zunovo has also been approved, which is given as an under-the-skin injection twice yearly, providing patients with an alternative delivery method.^[12]

Clinical studies have demonstrated that ocrelizumab can slow the progression of disability in people with PPMS. In a large trial involving 732 participants, those taking ocrelizumab showed a reduced risk of disability progression compared to those receiving a placebo. The medication also reduced the volume of brain lesions, which are areas of damage visible on MRI scans. While these results are encouraging, it’s important to understand that ocrelizumab slows progression rather than stopping it completely or reversing existing damage.^[12]

Like all medications, ocrelizumab can cause side effects. The most common are infusion reactions, which can include itching, rash, throat irritation, fever, fatigue, headache, dizziness, nausea, and rapid heartbeat. These reactions typically occur during the infusion or within 24 hours afterward. To reduce the risk of infusion reactions, patients usually receive medications before the infusion, such as corticosteroids and antihistamines.^[12]

Because ocrelizumab suppresses part of the immune system, it can increase the risk of infections. Patients may be more susceptible to respiratory tract infections, urinary tract infections, and viral infections. Before starting treatment, doctors typically screen for existing infections and ensure vaccinations are up to date. During treatment, patients need to be vigilant about reporting any signs of infection to their healthcare provider.^[7]

Beyond disease-modifying therapy, a substantial portion of PPMS treatment involves managing specific symptoms. Many people with PPMS experience muscle stiffness and spasticity, which can be treated with medications such as baclofen, tizanidine, or dantrolene. These drugs help relax muscles and reduce tightness, making movement easier and more comfortable.^[1]

Bladder and bowel problems are common in PPMS and can significantly impact quality of life. Various medications can help with urinary urgency, frequency, or retention. For example, anticholinergic medications may reduce bladder spasms, while intermittent catheterization might be necessary for some people who have difficulty emptying their bladder completely. Bowel management often involves a combination of dietary changes, adequate fluid intake, and sometimes medications to regulate bowel function.^[11]

Fatigue is one of the most challenging symptoms for many people with PPMS. While the underlying causes are complex and not fully understood, several approaches can help. Medications such as amantadine or modafinil are sometimes prescribed to combat fatigue. Equally important are lifestyle strategies, including energy conservation techniques, regular exercise adapted to individual abilities, and management of sleep problems that can worsen fatigue.^[1]

Physical therapy and occupational therapy play crucial roles in PPMS care throughout the course of the disease. Physical therapists design exercise programs to maintain strength, flexibility, and balance, helping people stay mobile for as long as possible. Occupational therapists help adapt daily activities and home environments to maintain independence as symptoms progress. These rehabilitation approaches are considered essential components of comprehensive PPMS care.^[11]

Pain management is another important aspect of treatment. Some people with PPMS experience neuropathic pain, which is pain caused by nerve damage. This type of pain often responds to medications like gabapentin or pregabalin, which are designed specifically for nerve-related pain. Muscle pain and spasms may require different approaches, including physical therapy, stretching exercises, and muscle relaxants.^[1]

Depression and mood changes are common in PPMS, both as direct effects of the disease on the brain and as responses to living with a progressive condition. Antidepressant medications, counseling, and support groups can all play important roles in maintaining mental health. Addressing mood and emotional wellbeing is considered just as important as treating physical symptoms.^[1]

Emerging Therapies in Clinical Trials

The limited number of approved treatments for PPMS has driven extensive research efforts to find new therapeutic approaches. Clinical trials are ongoing around the world, testing various strategies to slow disease progression, protect nerve cells, and improve symptoms. These studies represent hope for expanding the treatment options available to people living with PPMS in the coming years.^[10]

One active area of research involves testing different types of immunotherapies beyond ocrelizumab. Scientists are investigating whether other medications that target different parts of the immune system might be effective in PPMS. These approaches aim to reduce the immune system’s attack on the nervous system while preserving its ability to fight infections. Various monoclonal antibodies and small molecule drugs are being evaluated in different phases of clinical trials.^[10]

A particularly promising direction in PPMS research focuses on neuroprotection, which means protecting nerve cells and myelin from damage. Unlike treatments that target the immune system, neuroprotective therapies aim to directly shield nervous system cells from the degenerative processes that occur in progressive MS. Researchers are testing compounds that might support nerve cell survival, promote myelin repair, or reduce the toxic effects of inflammation on nerve tissue.^[10]

Some clinical trials are exploring medications that might promote remyelination, which is the repair of damaged myelin sheaths around nerve fibers. If successful, these approaches could potentially restore some lost function, not just slow further decline. Several compounds are being studied for their ability to stimulate the body’s own myelin-producing cells to repair damaged areas of the nervous system. This represents a fundamentally different approach from simply slowing disease progression.^[10]

Researchers are also investigating whether combinations of different treatments might be more effective than single therapies. For example, combining an immunotherapy with a neuroprotective agent might address both the immune attack and the nerve degeneration that characterize PPMS. These combination approaches are still in early phases of research, but they represent a logical strategy given the complex nature of the disease.^[10]

Clinical trials for PPMS typically follow a structured progression through three phases. Phase I trials primarily assess safety, testing new treatments in small groups of people to identify what doses can be tolerated and what side effects occur. Phase II trials involve larger groups and begin to evaluate whether the treatment shows signs of effectiveness in slowing disease progression or improving symptoms. Phase III trials are large-scale studies that compare the new treatment directly against existing standard treatments or placebo to definitively determine if it should be approved for general use.^[10]

Many clinical trials are being conducted across multiple countries, including sites in Europe, the United States, and other regions. This global approach helps ensure that research findings are applicable to diverse populations and allows more people to access experimental treatments. Eligibility for trials varies depending on the specific study, but typically includes factors such as confirmed PPMS diagnosis, disease duration, level of disability, and absence of certain other health conditions.^[10]

Some trials are investigating whether drugs already approved for other conditions might be beneficial in PPMS. This approach, called drug repurposing, can potentially bring new treatments to patients more quickly because safety data already exists. For example, certain medications used for other neurological or inflammatory conditions are being tested to see if they might slow PPMS progression.^[10]

Researchers are also exploring novel approaches such as stem cell therapies for PPMS. These experimental treatments aim to either repair damaged tissue or modulate the immune system in new ways. While stem cell research for MS has generated significant interest, it’s important to note that these approaches are still largely experimental and not yet proven effective or safe for routine use outside of clinical trials. Most medical organizations caution against seeking stem cell treatments outside of properly conducted clinical trials.^[9]

Advanced imaging techniques are playing an increasingly important role in clinical trials for PPMS. Researchers use sophisticated MRI scans to measure brain volume changes, detect subtle areas of damage, and track how well treatments might be preserving brain tissue. These imaging biomarkers help scientists assess whether experimental treatments are having biological effects even before changes in disability can be measured clinically.^[10]

Some clinical trials are focusing on specific symptoms of PPMS rather than overall disease progression. For example, studies might test new approaches for improving walking ability, reducing fatigue, or enhancing cognitive function. While these symptomatic treatments wouldn’t change the underlying disease course, they could significantly improve quality of life for people with PPMS.^[10]

Most common treatment methods

• Disease-modifying therapy
  • Ocrelizumab (Ocrevus) – the only approved medication for PPMS, given as intravenous infusion every six months after initial doses
  • Ocrevus Zunovo – subcutaneous version of ocrelizumab given as under-the-skin injection twice yearly
  • Works by destroying specific B cells involved in immune system attacks on the nervous system
• Symptom management medications
  • Muscle relaxants (baclofen, tizanidine, dantrolene) for spasticity and muscle stiffness
  • Bladder control medications (anticholinergics) for urinary urgency and frequency
  • Nerve pain medications (gabapentin, pregabalin) for neuropathic pain
  • Fatigue management drugs (amantadine, modafinil)
  • Antidepressants for mood changes and depression
• Rehabilitation therapies
  • Physical therapy to maintain strength, flexibility, and balance
  • Occupational therapy to adapt daily activities and maintain independence
  • Exercise programs tailored to individual abilities and limitations
• Experimental approaches in clinical trials
  • Alternative immunotherapies targeting different immune system components
  • Neuroprotective therapies to shield nerve cells from damage
  • Remyelination strategies to promote repair of myelin sheaths
  • Combination therapies using multiple treatment approaches
  • Drug repurposing studies testing medications approved for other conditions